MedTrace Logo

Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients

NCT04379817 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2024-06-27

No results posted yet for this study

Summary

This study wil assess somatostatin receptor (SSTR) expression via the uptake of Gallium-68 labelled DOTA-conjugated SSTR targeting peptide using PET/CT imaging in multiple myeloma lesions pre-identified on 18F-FDG PET/CT in order to evaluate the feasibility of molecular radionuclide therapy in refractory and relapsing mutiple myeloma using the Lutetium-177 radiolabelled targeting peptide.

Conditions

Interventions

DIAGNOSTIC_TEST

Gallium-68 labelled DOTA-conjugated SSTR targeting peptide PET/CT

Assess somatostatin receptor expression

Sponsors & Collaborators

  • Jules Bordet Institute

    lead OTHER

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-25
Primary Completion
2024-05-23
Completion
2024-05-23

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04379817 on ClinicalTrials.gov